Recent

% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

  • taexpert928 taexpert928 Feb 15, 2013 1:40 PM Flag

    Overall survival of 30.4 months for bortezomib relapsed patients in Phase 2 of AEZS-108

    At the 2011 ASH meeting, Dr. Paul Richardson, MD, Associate Professor in the department of medicine at Harvard Medical School, presented the final data for one of these Phase 1/2 trials which he conducted in 73
    Very good results in phase 2 should bring very good results of phase 3 on Monday
    ___________________________________________________________________
    patients. Results showed a median overall survival of 25 months for all evaluable patients, including 30.4 months for 20 bortezomib relapsed patients and 22.5 months for 53 bortezomib refractory patients.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AEZS
0.1816-0.0075(-3.97%)Jul 31 3:59 PMEDT